Cadrenal Therapeutics, Inc.
Novel anticoagulant biopharmaceuticals for acute and chronic thrombotic disorders
- Sector
- Biotech
- Headquarters
- PONTE VEDRA, FL
- Founded
- 2022
- Latest Form D
- $7.9M, Apr 2026
- Total capital
- $29.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $29.6M
- 6 Form D · last Apr 2026
- 7 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 12 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$7.9M
- Private capital raisedForm D · SEC · 5th filing$4.4M
- Private capital raisedForm D · SEC · 4th filing$9.4M
- Private capital raisedForm D · SEC · 3rd filing$7.5M
- Private capital raisedForm D · SEC · 2nd filing$250K
- Private capital raisedForm D · SEC · 1st filing$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Douglas W. LosordoExecutive OfficerNamed in SEC Form D filings
- Glynn WilsonDirectorNamed in SEC Form D filings
- JAMES J. FERGUSONExecutive OfficerNamed in SEC Form D filings
- Jeff W. ColeExecutive OfficerNamed in SEC Form D filings
- JEFFREY K. COLEExecutive OfficerNamed in SEC Form D filings
- John R. MurphyDirectorNamed in SEC Form D filings
Show all 11 people
- Lee R. GoldenDirectorNamed in SEC Form D filings
- Matthew SzotExecutive OfficerNamed in SEC Form D filings
- QUANG X. PHAMExecutive Officer, DirectorNamed in SEC Form D filings
- Robert W. LisickiDirectorNamed in SEC Form D filings
- Steven R. ZelenkofskeDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 12- Pending12-LIPOXYGENASE Inhibitors For The Treatment Of LupusUSPTOApplication 19128392
- PendingMethod For Preventing Coagulation In Patients With Implanted Cardiac DevicesUSPTOApplication 19067803
- PendingTherapeutic Compounds And CompositionsUSPTOApplication 18797184
Show all 12 patent records
- 12-LIPOXYGENASE Inhibitors For The Treatment Of LupusFeb 19, 2026 · Application 19128392Pending
- Method For Preventing Coagulation In Patients With Implanted Cardiac DevicesSep 4, 2025 · Application 19067803Pending
- Therapeutic Compounds And CompositionsJul 3, 2025 · Application 18797184Pending
- Compositions And Methods Of Use To Treat 12-LIPOXYGENASE (12-LOX) Mediated DiseasesFeb 27, 2025 · Application 18723072Pending
- Aqueous Parenteral Pharmaceutical Formulations Containing 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) Benzenesulfonamide DerivativesFeb 20, 2025 · Application 18723045Pending
- Therapeutic Compounds, Compositions, And Methods Of Use ThereofJul 13, 2023 · Application 18122519Pending
- Oral Pharmaceutical Formulations Containing 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) Benzenesulfonamide DerivativesApplication 19125889Pending
- Method Of Treating Advanced Heart FailureApplication 63560351Pending
- Compositions And Methods Of Use To Treat 12-LIPOXYGENASE (12-LOX) Mediated DiseasesApplication 63509699Pending
- Method For Preventing Coagulation In Patients With Implanted Cardiac DevicesApplication PCTUS2025018009Pending
- Oral Pharmaceutical Formulations Containing 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) Benzenesulfonamide DerivativesApplication 63382032Pending
- Methods For Treating Heparin-induced ThrombocytopeniaApplication PCTUS2025021760Pending
Related companies, and why
- STEM CELL THERAPEUTICS CORPSimilar federal contract value in Biotech · null in contracts
- Guardian Therapeutics, LLCSimilar federal contract value in Biotech · null in contracts
- Nexo TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Immunitas TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Therini BioSimilar federal contract value in Biotech · null in contracts
- EnteroBiotix LTDSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .